Summary
Ovagen is aiming to transform the egg-based production of vaccines and other biopharmaceutical medicines by producing the world’s first Germ Free egg and bringing it into mass production.
The proposed programme of work will build on the groundwork initiated as part of the 30 month OvaVax project (GA 858390) and provides a logical expansion of this disruptive, innovative technology to the challenges facing the world as it comes to grips with COVID-19 and future pandemics with the need for rapid scale-up of vaccine production
Ovagen is applying for EIC Accelerator funding to broaden the project scope of their existing H2020 SME Instrument Phase 2 to expand and accelerate the existing influenza project, to include COVID-19, Yellow Fever, Newcastle Disease and to include readiness for production and accelerated international scaleup of germ free egg production to increase global vaccine manufacturing capacity in readiness for future pandemics similar to COVID-19.
The proposed programme of work will build on the groundwork initiated as part of the 30 month OvaVax project (GA 858390) and provides a logical expansion of this disruptive, innovative technology to the challenges facing the world as it comes to grips with COVID-19 and future pandemics with the need for rapid scale-up of vaccine production
Ovagen is applying for EIC Accelerator funding to broaden the project scope of their existing H2020 SME Instrument Phase 2 to expand and accelerate the existing influenza project, to include COVID-19, Yellow Fever, Newcastle Disease and to include readiness for production and accelerated international scaleup of germ free egg production to increase global vaccine manufacturing capacity in readiness for future pandemics similar to COVID-19.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190136873 |
| Start date: | 01-11-2022 |
| End date: | 31-10-2024 |
| Total budget - Public funding: | 3 571 428,75 Euro - 2 500 000,00 Euro |
Cordis data
Original description
Ovagen is aiming to transform the egg-based production of vaccines and other biopharmaceutical medicines by producing the world’s first Germ Free egg and bringing it into mass production.The proposed programme of work will build on the groundwork initiated as part of the 30 month OvaVax project (GA 858390) and provides a logical expansion of this disruptive, innovative technology to the challenges facing the world as it comes to grips with COVID-19 and future pandemics with the need for rapid scale-up of vaccine production
Ovagen is applying for EIC Accelerator funding to broaden the project scope of their existing H2020 SME Instrument Phase 2 to expand and accelerate the existing influenza project, to include COVID-19, Yellow Fever, Newcastle Disease and to include readiness for production and accelerated international scaleup of germ free egg production to increase global vaccine manufacturing capacity in readiness for future pandemics similar to COVID-19.
Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATORCHALLENGES-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
